| ￥4500 | |
| Z05567-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by Bis-Tris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Immobilized Latent TGF beta 3, His, Human at 2μg/ml (100μl/well) on the plate can bind Human TGF?beta RII, mFc Tag. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 45.9 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 46-60 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in 20mM PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background | Transforming growth factor-betas (TGF-βs) are multifunctional cytokines that have been implicated in the regulation of a broad range of biological processes, including cell proliferation, cell survival, and cell differentiation. And transforming growth factor beta3 (TGFbeta3) is a key protein involved in scar-free healing observed in embryos. |
| Synonyms | TGFB3; ARVD; TGF-beta3; TGF-β; TGFβ3; TGFβ |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
